scPharmaceuticals Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
May 16, 2022 07:10 ET
|
scPharmaceuticals, Inc.
FDA assigns PDUFA action date of October 8, 2022 Continuing to ramp up commercial readiness activities in advance of an anticipated Q4 2022 launch of FUROSCIX®, if approved Ended Q1 with cash, cash...
scPharmaceuticals Inc. Announces FDA Acceptance of FUROSCIX® New Drug Application
May 16, 2022 07:00 ET
|
scPharmaceuticals, Inc.
PDUFA action date set for October 8, 2022 Company preparing for Q4 commercial launch, if approved BURLINGTON, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a...
scPharmaceuticals Inc. Announces Resubmission of FUROSCIX® New Drug Application
April 11, 2022 07:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 22, 2022 07:00 ET
|
scPharmaceuticals, Inc.
Successfully completed all testing; plan to re-submit FUROSCIX® NDA by April 15, 2022 Commercial preparedness activities ramping up to support anticipated Q4 2022 launch of FUROSCIX, if approved ...
scPharmaceuticals to Present at the 42nd Annual Cowen Healthcare Conference
February 16, 2022 16:05 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 03, 2022 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals to Participate in Two Upcoming Investor Conferences
December 20, 2021 16:05 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
November 09, 2021 07:00 ET
|
scPharmaceuticals, Inc.
All additional testing of devices manufactured on the planned commercial line, as required by the FDA, has been successful to date FUROSCIX® NDA resubmission anticipated for Q1 2022 due to COVID-19...
scPharmaceuticals to Present at the Jefferies London Healthcare Conference
November 02, 2021 08:30 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Presents Late-breaking FREEDOM-HF Study Data at the Heart Failure Society of America Annual Scientific Meeting 2021
September 10, 2021 08:00 ET
|
scPharmaceuticals, Inc.
Data show statistically significant and meaningful reduction in both heart failure-related and overall healthcare costs for patients treated with FUROSCIX® versus a historical comparator group ...